When Vanessa, a travel nurse from Memphis, Tennessee, received a stage 3 triple-negative breast cancer diagnosis, her carefully planned future was abruptly interrupted. The most aggressive subtype of breast cancer, triple-negative, required immediate and intensive treatment. As a nurse, she had cared for patients throughout her career, but facing the disease herself revealed unfamiliar challenges. “I’ve taken care of patients my whole life,” she says. “But I didn’t really know what breast cancer truly entailed.”
Despite her medical background, the emotional and physical toll was immense. After initial treatment, devastating news arrived: the cancer had metastasized, becoming metastatic triple-negative breast cancer. “When I found out I had metastatic breast cancer, it was just an awful feeling to know you have to go through treatment again,” she recalls. For many patients, the first treatment after metastasis is crucial, as it may be the only opportunity to halt progression. Triple-negative breast cancer grows and spreads faster than other types, and it disproportionately affects younger women, as well as Black and Hispanic women, making access to the latest education a matter of survival.
Vanessa sought to understand her options thoroughly. Historically, treatment for metastatic triple-negative breast cancer relied heavily on chemotherapy, which affects all rapidly dividing cells. However, her doctor suggested a clinical trial for a newer class of medicine called antibody-drug conjugates (ADCs). Unlike traditional chemo, ADCs are designed to target specific markers on cancer cells, delivering treatment more directly and potentially reducing harm to healthy cells. Until recently, ADCs were reserved for later lines of therapy, but now they may be used as a first-line treatment after metastasis. This innovation has already helped many patients by keeping the cancer from growing, allowing them to plan their lives more predictably.
Not all ADCs are identical; safety and efficacy vary. While not every patient qualifies, understanding when ADCs might be considered and their impact on daily life can empower patients during discussions with their care team. Dr. Gregory Vidal, Vanessa's oncologist and Director of Clinical Research at West Cancer Center, emphasizes, “When selecting treatment, it’s important to consider patients’ goals, wishes and needs so that we can try to realistically plan around those. All patients are different and may qualify for different ADCs.” He encourages patients to ask questions about treatment goals at each stage of care.
Living with metastatic breast cancer often means ongoing treatment to manage the disease and maintain quality of life. Vanessa leaned on her support system, focusing on “faith over fear” and planning activities around her treatment schedule. Her advice to others: stay positive, ask questions, and advocate for yourself. “You definitely have a fight in front of you, but you can get through this,” she says. “You have to do your research and get answers.”
Vanessa's story highlights the importance of staying informed about emerging therapies like ADCs and the need for patients to actively participate in treatment decisions. For more insights, visit Expose-MBC.com/ADC.
